Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)
This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC patients.
Lung Adenocarcinoma
DRUG: Furmonertinib
Objective Response Rate (ORR), Proportion of patients whose tumors were assessed as complete response(CR) or partial response(PR) according to RECIST 1.1, Approximately 8 weeks following the first dose of study drug
Disease Control Rate (DCR), Proportion of patients whose tumors were assessed as CR, PR or stable disease (SD) according to RECIST 1.1, Approximately 8 weeks following the first dose of study drug|Progression free survival (PFS), The time from the first does of the study drugs to the progression of the disease or death for any reason., Approximately 3 years following the first dose of study drug|Disease free survival (DFS), The time from the end of surgery to the progression of the disease or death for any reason., Approximately 3 years following the first dose of study drug|Adverse Events (AEs), The number of patients with adverse events and the severity according to CTCAE v5.0, From the start of study drug to 28 days after the last dose of study drug
Circulating tumor DNA clearance rate, The proportion of patients with circulating tumor DNA clearance after neoadjuvant therapy, Approximately 8 weeks following the first dose of study drug|Minimal residual disease rate, The proportion of patients with minimal residual disease defined as detectable ctDNA with a variant allele fraction of at least 0.1% in plasma after surgery, Approximately 12 weeks following the first dose of study drug
Please refer to detailed description in the following context.